Decreased TMED4 due to CER treatment may have contributed to slowing glioma progression, as supported by Ullah et al.’’ [47] finding that TMED4 expression is negatively correlated with the survival rate of GB patients. The gene discussed is TMED4; the disease is central nervous system cancer.